2015年后美国FDA批准的孤儿药分析Analysis of the orphan drugs approved by FDA since 2015
王雪飞,周林波,李文睿,陈国良
WANG Xue-fei,ZHOU Lin-bo,LI Wen-rui,CHEN Guo-liang
摘要(Abstract)：
目的介绍2015年以来美国FDA批准的孤儿药。方法查阅近年来国内外相关文献,对其进行分析和归纳总结。结果孤儿药在抗肿瘤、抗代谢病、抗菌、抗高血压以及其他领域发展迅速。结论孤儿药发展迅速,随着精准医疗的发展,孤儿药具有良好的开发前景。
Objective To introduce the orphan drugs approved by FDA since 2015.Methods Analyze and summarize combining with related literatures.Results The orphan drugs have developed rapidly in the domains of antineoplastic,anti-metabolic,anti-microbial,anti-hypertension and others.Conclusions The orphan drugs grow quickly and have a favorable development prospect.
关键词(KeyWords)：
FDA;孤儿药;进展
food and drug administration;the orphan drugs;progress
基金项目(Foundation): 国家基础学科人才培养基金资助项目(J1103606)
作者(Author):
王雪飞,周林波,李文睿,陈国良
WANG Xue-fei,ZHOU Lin-bo,LI Wen-rui,CHEN Guo-liang
DOI: 10.14066/j.cnki.cn21-1349/r.2017.06.014
参考文献(References)：
- [1]欧文.获FDA孤儿药资格认定的药物数创新高[N].医药经济报.2016-2-24(A08).
- [2]陶勇,邵元福,张纯,等.美国罕用药管理的历史与现状[J].中国药学杂志,2001,36(9):634-636.
- [3]刘玉聪,董江萍.欧盟罕见病及孤儿药管理现状的研究[J].中国药学杂志,2012,47(5):395-398.
- [4]龚时薇.促进我国罕见病患者药品可及性的管理策略研究[D].武汉:华中科技大学,2008.
- [5]马瑞,李定国,张学,等.中国罕见病防治的机遇和挑战[J].中国循证儿科杂志,2011,6(2):81-82.
- [6]GIUSEPPE R,ARIELA B,FINKELSTEIN F O,et al.Kidney failure:aims for the next 10years and barriers to success[J].Lancet,2013,382(9889):353
- [7]樊泳希,李永萍.硼替佐米和来那度胺治疗多发性骨髓瘤的临床应用进展[J].医药前沿,2016,6(1):182-183.
- [8]王彦明,钟武,周辛波.口服布鲁顿酪氨酸激酶抑制剂——依鲁替尼[J].临床药物治疗杂志,2015,13(4):21-24.
- [9]夏训明.美国FDA批准Halaven(eribulin mesylate)用于治疗脂肪肉瘤[J].广东药学院学报,2016,32(1):110-110..
- [10]SAKAMOTO H,TSUKAGUCHI T,HIROSHIMA S,et al.CH5424802,a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant[J].Cancer Cell,2011,19(5):679-690.
- [11]LATIF M,SAEED A,KIM S H.Journey of the ALK-inhibitor CH5424802to phaseⅡclinical tria[J].Pharmaceutical Research,2013,36(9):1051-1054.
- [12]LATIF M,SAEED A,KIM S H.Journey of the ALK-inhibitor CH5424802to phaseⅡclinical tria[J].Archives of Pharmacal Research,2013,36(9):1051-1054.
- [13]王晓坤,胡心亭.肾病型胱胺酸症治疗药——Procysbi[J].药学研究,2013,32(6):371-372.
- [14]NICO D.Targeting agenetic defect:cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis[J].European Respiratory Journal,2013,22(127):58-65.
- [15]叶成添,林跃生,唐细兰,等.他克莫司滴眼液与环孢素A滴眼液在全角膜移植术后免疫排斥反应的疗效观察[J].广东药学,2004,14(6):43-44.
- [16]黄淑芬,戴晓帆.原发性周期性麻痹患者红细胞膜Na-K-ATPase的活性变化[J].当代医学,2014,20(10):86-87.
- [17]林飞燕,谢宗宙,朱燕兴.恶性黑色素瘤治疗新药CTLA-4抗体lpihmumab的研究进展[J].现代肿瘤医学,2012,20(9):1962-1966.
- [18]刘祥祥,王丽娜,杨伟林,等.滤泡性淋巴瘤的治疗进展[J].中国实验血液学杂志,2014,22(1):182-186.
- [19]夏训明.美国FDA批准Kanuma治疗溶酶体酸性脂肪酶(LAL)缺乏症[J].广东药学院学报,2015,31(6):832-832.
- [20]杨欣,冯四洲.去纤苷防治造血干细胞移植后肝静脉闭塞病的研究进展[J].白血病:淋巴瘤,2013,22(7):389-392.
- [21]EVALUATE P.2015年孤儿药研发分析报告(Ⅰ)[J].药学进展,2016,40(1):62-68.